Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22305066 | 0.87 | SMN1; SMN2 (0.33) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL13286238 | 0.87 | GBA1 (0.38) | SMN1; SMN2 | |
| SCHEMBL15825594 | 0.82 | ATM (0.31) | SMN1; SMN2 | |
| SCHEMBL17433058 | 0.82 | ATM (0.31) | SMN1; SMN2 | |
| SCHEMBL12425829 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL21138054 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL21705262 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL16508784 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL14071748 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL12561242 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | SMN1; SMN2 1243/4885GNAI3 601/4885GNAO1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.